According to the “Global Allergic Rhinitis Market Overview” report provided by Marketresearchfuture, the size of the allergic rhinitis market was $13.9 billion in 2021, $14.35 billion in 2022, and is expected to grow to $18.02 billion by 2030. The compound annual growth rate (CAGR) for the forecast period (2022-2030) is 3.30%. The market size for allergic rhinitis in North America in 2021 was 6.0048 billion US dollars, showing a significant compound annual growth rate during the research period. The European allergic rhinitis market holds one of the largest market shares, the German allergic rhinitis market holds the largest market share, and the UK allergic rhinitis market is the fastest-growing market in the European region. It is expected that the allergic rhinitis market in the Asia Pacific region will grow at the fastest compound annual growth rate from 2022 to 2030. The high demand for advanced technology and the high incidence of respiratory diseases are driving the growth of the allergic rhinitis drug market in the region. The Chinese allergic rhinitis market holds the largest market share, while the Indian allergic rhinitis market is the fastest-growing market in the Asia Pacific region.
The main participants in the allergic rhinitis market, such as AstraZeneca, GlaxoSmithKline, Johnson&Johnson Services, Bayer, ALK Abell ó A/S, Glenmark, etc., are striving to expand market demand through investment in research and development activities. Major market participants are investing heavily in research and development to expand their product lines, which will help further growth in the allergic rhinitis market. Market participants have also taken a series of strategic measures to expand their global influence. The treatment of allergic rhinitis relies on antihistamines, corticosteroids, immunotherapy, etc.
Is there any better new way?
Yes!
CBD is a non psychoactive chemical substance found in cannabis plants (specifically cannabis), which has been extensively studied over the past few decades and ultimately approved by the World Health Organization (WHO). It has been proven to help treat various diseases, from skin acne to anxiety, post-traumatic stress disorder, and even pain and exercise injuries from heart disease and cancer.
Related scientific research
Future Omics published an article “[Traumatic Stress] Beijing Institute of Radiomedicine (IF=14.9): Cannabinediol Inclusion Nasal Thermosensitive Hydrogel for the Treatment of Posttraumatic Stress Disorder” on September 25, 2022. It recommended an article “Cannabinediol Inclusion Nasal Thermosensitive Hydrogel for the Treatment of Posttraumatic Stress Disorder” published in Acta Pharmaceutica Sinica B (IF: 14.9) by the Pharmaceutical Department of Beijing Institute of Radiomedicine, School of Pharmacy of Shandong University of Chinese Medicine and other research teams. Important information is extracted as follows:
Compared with oral administration, the relative bioavailability of CBD in the blood, brain, and liver were 693%, 313%, and 77.9%, respectively (Table 4). The concentration of CBD in the blood and brain is significantly higher than that through oral administration. Compared with oral administration, nasal administration of CBD has less distribution in the liver, avoiding first pass effects and less toxicity to the liver. The Tmax of nasal administration is significantly shorter than that of oral administration, indicating that nasal administration has a faster impact on post-traumatic stress disorder.
conclusion
In this study, CBD TSG was prepared based on the physiological conditions of the nasal cavity. After a series of evaluations, the preparation is safe and effective, with controllable quality. Due to the brain targeting nature of nasal administration, CBD TSGs have a good therapeutic effect on post-traumatic stress disorder. In summary, this study has prepared safe, effective, and quality controllable brain targeted formulations, providing a new option for clinical treatment of post-traumatic stress disorder. But its mechanism of action still needs further research.